CD4 News and Research

RSS

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

16 May 2021

Unique pre-clinical model enables study of HIV infection and testing of new therapies

A team led by researchers at Weill Cornell Medicine and Children's National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.

14 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

A new study released as a bioRxiv* preprint tried to establish how tissues such as the upper respiratory tract (URT) – which harbor the virus and often act as the point of entry – are difficult to access for routine testing, but are responsive to vaccination.

11 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

A new study shows that the immunological features of severe COVID-19 are already present in healthy older adults and in men, before they are infected, indicating a possible explanation for this differential susceptibility towards the virus.

6 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Recovered COVID-19 patients show signs of long-term immunity

A study conducted by researchers in the United States has found that most patients who recovered from coronavirus disease 2019 (COVID-19) showed signs of long-lasting immunity against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Apr 2021

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

In the 40-some years since the beginning of the HIV/AIDS epidemic, scientists have learned a lot about the virus, the disease, and ways to treat it. But one thing they still don't completely understand is which exact cells are most susceptible to HIV infection.

28 Apr 2021

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

However, with the waning of the immune response, it is not clear if these older people respond to the vaccine as well as younger individuals do. A recent study explored this question and found that though the antibody levels were somewhat lower in this group, they were still robust. This is a promising observation.

26 Apr 2021

Potential new COVID vaccine from Australia

Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.

26 Apr 2021

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Researchers in the UK have shown that a single dose of the Pfizer-BioNTech vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced antibody and cellular responses in patients with chronic myeloid leukemia (CML) who were taking tyrosine kinase inhibitors.

25 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Widely available HIV testing and treatment services increase life expectancy

Life expectancy among adults living with HIV receiving antiretroviral therapy (ART) in Latin America and the Caribbean has increased significantly since HIV testing and treatment services became more widely available, according to research published today in The Lancet HIV journal.

21 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

CD4 News and Research

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Unique pre-clinical model enables study of HIV infection and testing of new therapies

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Recovered COVID-19 patients show signs of long-term immunity

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

Potential new COVID vaccine from Australia

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Widely available HIV testing and treatment services increase life expectancy

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News